Change in general HRQOL and patients’ perception of change
CML
Overall HRQOL as assessed by the EQ-5D-5L VAS remained similar to baseline in both arms during treatment. As observed in the analysis of MDASI-CML symptom and interference scores, there was a trend of improvement from baseline in HRQOL reported in the asciminib arm (4.8 points on the 0–100 VAS [95% CI 2.4, 7.2]), although it did not reach the published clinically meaningful threshold (MID of 7 points). In addition, there was no clinically meaningful difference in changes from baseline between treatment arms (treatment difference 3.9 [−0.5, 8.2]) (Supplementary Table The PGIC-CML is a single question assessing patient self-report of change in CML symptom severity since the start of treatment. Considering all patients randomized on each arm (